Can escitalopram and sertraline be taken together with levetiracetam (Keppra) in a patient with depression, seizure disorder, and marijuana use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can You Take Escitalopram and Sertraline with Keppra for Depression and Seizure Disorder with Marijuana Abuse?

You should NOT take both escitalopram and sertraline together, but you CAN safely use ONE of these SSRIs (preferably escitalopram or sertraline) with levetiracetam (Keppra) for treating depression in a patient with seizure disorder and marijuana use.

Critical Issue: Combining Two SSRIs

The most important problem here is taking both escitalopram AND sertraline simultaneously. This is not recommended practice. Guidelines explicitly state there is limited evidence supporting the use of two antidepressants from the same class as an initial treatment approach 1. The only acceptable scenario for dual SSRI use is during a brief transition period when switching from one to another 1.

Combining two SSRIs significantly increases the risk of serotonin syndrome, which can be life-threatening with symptoms including mental status changes, neuromuscular hyperactivity (tremors, rigidity, hyperreflexia), autonomic instability (hypertension, tachycardia), and in severe cases, seizures, arrhythmias, and death 2.

SSRIs with Levetiracetam: Safe Combination

Using a SINGLE SSRI with levetiracetam is generally safe and appropriate. Here's the evidence:

Seizure Risk with SSRIs

  • SSRIs should be used cautiously in patients with seizure disorders, but they are NOT contraindicated 2
  • Guidelines recommend close monitoring when prescribing SSRIs to patients with seizure history 2
  • Research evidence shows that sertraline, citalopram, escitalopram, and other SSRIs are among the safest antidepressants for people with epilepsy 3
  • A systematic review found that SSRIs (particularly sertraline and citalopram) did not significantly increase seizure frequency in epilepsy patients 4

Drug Interactions Between SSRIs and Levetiracetam

Escitalopram/citalopram has the LEAST potential for drug interactions among SSRIs because it has minimal effect on CYP450 enzymes 2. This makes it the preferred choice when combining with other medications.

Research specifically examining levetiracetam-SSRI interactions shows:

  • Pharmacodynamic interactions between levetiracetam and SSRIs have been identified but are generally manageable 5
  • Animal studies showed sertraline combined with levetiracetam required careful monitoring but was feasible 6

Marijuana Use Considerations

The marijuana abuse adds complexity:

  • Cannabis can interact with SSRIs through CYP450 pathways, particularly cannabidiol (CBD) which significantly inhibits metabolism of citalopram/escitalopram 7
  • If the patient is using cannabis products high in CBD, this could increase SSRI blood levels and adverse effects 7
  • One study showed escitalopram provided no additional benefit for cannabis withdrawal symptoms 8, but this doesn't preclude its use for treating comorbid depression

Specific Recommendations

Choose ONE of the following approaches:

  1. First-line choice: Escitalopram + Levetiracetam

    • Start escitalopram at low dose (5-10 mg daily)
    • Escitalopram has lowest drug interaction potential 2
    • Monitor closely for behavioral activation in first month 2
    • Titrate slowly over 1-2 week intervals 2
  2. Alternative: Sertraline + Levetiracetam

    • Start sertraline at 25-50 mg daily
    • Sertraline is well-studied in epilepsy populations 3, 4
    • Titrate over 1-2 week intervals 2
    • Monitor for discontinuation syndrome if dose changes needed 2

Critical Monitoring Requirements

Monitor closely for:

  • Serotonin syndrome symptoms in first 24-48 hours after starting or dose changes 2
  • Seizure frequency changes - document baseline and track any increases 9, 10
  • Behavioral activation/agitation especially in first month 2
  • Suicidality particularly in first months of treatment 2
  • If using cannabis with high CBD content, watch for increased SSRI side effects (nausea, sedation, sexual dysfunction) suggesting elevated drug levels 7

Levetiracetam-Specific Cautions

Be aware that levetiracetam itself can cause:

  • Behavioral side effects including anxiety, agitation, depression, and rarely acute aggression 11, 12
  • These psychiatric effects may be more common in patients with pre-existing psychiatric conditions 11
  • If behavioral problems emerge, it may be difficult to distinguish whether they're from the SSRI, levetiracetam, or the underlying conditions 12

Common Pitfalls to Avoid

  1. Never combine two SSRIs - choose one and optimize its dose
  2. Don't start both medications simultaneously - if possible, establish seizure control with levetiracetam first, then add SSRI
  3. Don't ignore cannabis use - counsel patient that high-CBD cannabis products may increase SSRI levels
  4. Don't use rapid titration - slow dose increases reduce risk of behavioral activation and seizures 2
  5. Don't abruptly discontinue SSRIs - taper gradually to avoid discontinuation syndrome, which can include seizures 2, 9

References

Guideline

practice parameter on the use of psychotropic medication in children and adolescents.

Journal of the American Academy of Child and Adolescent Psychiatry, 2009

Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

Research

Antidepressants in epilepsy.

Neurologia i neurochirurgia polska, 2018

Research

Antidepressants for people with epilepsy and depression.

The Cochrane database of systematic reviews, 2014

Research

Levetiracetam for managing neurologic and psychiatric disorders.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.